The company achieved an EBITDA (earnings before interest, tax, depreciation and amortisation) of Rs 2,884 crore, with an EBITDA margin of 26.8 percent.At 2:28 pm, Sun Pharma was trading Rs 43 higher at Rs 937.35 on the National Stock Exchange. The employee cost was 0.7 percent lower in the June quarter. Sequentially, however, there was a decline of 4.6 percent in the cost of raw materials and a 1.8 percent drop in other expenses. The company's cost of raw materials consumed, other expenses as well as employee costs as a percentage of revenue increased by 2.5 percent, 1.9 percent and 1.2 percent, respectively, from the Q1FY22. The company saw a lower other income of Rs 2.1 crore during the quarter, much lower than Rs 152.5 crore during the corresponding period of the last year and Rs 113.5 crore in the previous quarter. "Rest of World" recorded formulation sales of $ 190 million, up 2.6 percent over the same quarter last year. US formulation sales at $ 420 million grew 10.7 percent over the year-ago quarter, while the Emerging Markets formulation sales at $ 245 million were up 12.6 percent from the year-ago quarter. On reported basis (including Covid product sales), the growth is 2.4 percent over the year-ago period India formulation sales at Rs 3,387 crore were up 13 percent on like-to-like basis, excluding Covid products sales during the first quarter of the previous fiscal.
The company reported healthy margins despite rising costs, as it continued to focus on expanding its global specialty business and improving its market share, he added. Buy Sun Pharmaceutical Industries sun pharma moneycontrol Sun Pharma Q1 Review: All Eyes On The sun pharma moneycontrol Sun Pharma Share Price Hits New.
Unlocking opportunities in Metal and Mining.
#Sun pharma moneycontrol series#
Interview Series Business In The Week Ahead.
0 kommentar(er)
